Application No. 10/780,103
Amendment Dated July 21, 2005
Reply to Office Action of April 22, 2005

Listing of Claims:

1-48. (Canceled)

49. (Previously Presented) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)- $1\alpha,25$ -dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D_3 having the structure

50-53. (Canceled)

- 54. (Previously Presented) The method of claim 49 wherein the compound is administered orally.
- 55. (Previously Presented) The method of claim 49 wherein the compound is administered parenterally.
- 56. (Previously Presented) The method of claim 49 wherein the compound is administered transdermally.
- 57. (Previously Presented) The method of claim 49 wherein said effective amount comprises about $0.01\mu g/day$ to about $100\mu g/day$ of $20(S)-1\alpha,25$ -dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D₃.
- 58. (Previously Presented) The method of claim 49 wherein said effective amount comprises about $0.1\mu g/day$ to about $50\mu g/day$ of $20(S)-1\alpha,25$ -dihydroxy-2-methylene-26,27-dihomo-19-norvitamin D₃.

59. (Previously Presented) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃ having the structure

60-63. (Canceled)

- 64. (Previously Presented) The method of claim 59 wherein the compound is administered orally.
- 65. (Previously Presented) The method of claim 59 wherein the compound is administered parenterally.
- 66. (Previously Presented) The method of claim 59 wherein the compound is administered transdermally.
- 67. (Previously Presented) The method of claim 59 wherein said effective amount comprises about $0.01\mu g/day$ to about $100\mu g/day$ of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D_3 .
- 68. (Previously Presented) The method of claim 59 wherein said effective amount comprises about $0.1\mu g/day$ to about $50\mu g/day$ of 20(S)-26,27-dimethylene-25-methoxy-2-methylene-19-norvitamin D₃.
- 69. (Previously Presented) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer

Application No. 10/780,103 Amendment Dated July 21, 2005 Reply to Office Action of April 22, 2005

comprising administering to a patient with said disease an effective amount of 20(S)- 1α ,25-dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D₃ having the structure

70-73. (Canceled)

- 74. (Previously Presented) The method of claim 69 wherein the compound is administered orally.
- 75. (Previously Presented) The method of claim 69 wherein the compound is administered parenterally.
- 76. (Previously Presented) The method of claim 69 wherein the compound is administered transdermally.
- 77. (Previously Presented) The method of claim 69 wherein said effective amount comprises about $0.01\mu g/day$ to about $100\mu g/day$ of $20(S)-1\alpha,25$ -dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D₃.
- 78. (Previously Presented) The method of claim 69 wherein said effective amount comprises about $0.1\mu g/day$ to about $50\mu g/day$ of $20(S)-1\alpha,25$ -dihydroxy-26,27-dimethylene-2-methylene-19-norvitamin D₃.
- 79. (Previously Presented) A method of treating a cancerous disease selected from the group consisting of leukemia, colon cancer, breast cancer and prostate cancer comprising administering to a patient with said disease an effective amount of 20(S)-26,27-dimethylene- 1α -hydroxy-2-methylene-24-dehydro-19-norvitamin D_3 having the structure

- 4 -

Application No. 10/780,103 Amendment Dated July 21, 2005 Reply to Office Action of April 22, 2005

80-83. (Canceled)

- 84. (Previously Presented) The method of claim 79 wherein the compound is administered orally.
- 85. (Previously Presented) The method of claim 79 wherein the compound is administered parenterally.
- 86. (Previously Presented) The method of claim 79 wherein the compound is administered transdermally.
- 87. (Previously Presented) The method of claim 79 wherein said effective amount comprises about $0.01\mu g/day$ to about $100\mu g/day$ of 20(S)-26,27-dimethylene- 1α -hydroxy-2-methylene-24-dehydro-19-norvitamin D₃.
- 88. (Previously Presented) The method of claim 79 wherein said effective amount comprises about $0.1\mu g/day$ to about $50\mu g/day$ of 20(S)-26,27-dimethyl- 1α -hydroxy-2-methylene-24-dehydro-19-norvitamin D_3 .

- 5 -